10-Q: Strata Skin Sciences Reports Mixed Q2 Results Amidst Strategic Shifts

Strata Skin Sciences experienced a slight revenue increase in Q2 2024, but faced challenges with profitability and a decrease in XTRAC system placements.

Summary

• Strata Skin Sciences reported a net revenue of $8.435 million for the three months ended June 30, 2024, a slight increase from $8.250 million in the same period last year.
• The company's gross profit for the quarter was $4.937 million, up from $4.318 million in Q2 2023, with a gross profit margin of 58.5%.
• However, the company reported a net loss of $99,000 for the quarter, a significant improvement from a net loss of $3.148 million in Q2 2023.
• For the six months ended June 30, 2024, net revenue was $15.189 million, down from $15.817 million in the same period last year.
• The company's net loss for the first half of 2024 was $3.467 million, compared to a net loss of $5.983 million in the first half of 2023.
• The number of XTRAC systems placed in dermatologists' offices in the U.S. decreased to 882 as of June 30, 2024, from 923 at the end of 2023.
• The company sold 24 international and 4 domestic XTRAC systems in Q2 2024.
• Strata received $864,000 from the Employee Retention Credit in the first half of 2024.
• The company completed a 1-for-10 reverse stock split on June 6, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are improvements in net loss and gross profit margin, there are also concerns about revenue decline, a decrease in XTRAC system placements, and ongoing risks. The company's strategic shifts and cost-cutting measures are positive, but the overall outlook is uncertain.

Positives

• The company's gross profit margin increased to 58.5% in Q2 2024, driven by the sale of refurbished units and lower amortization costs.
• The net loss improved significantly in both Q2 and the first half of 2024 compared to the same periods in 2023.
• The company received a substantial benefit from the Employee Retention Credit.
• The company has been actively managing operating expenses, leading to lower costs in engineering, product development, and selling and marketing.

Negatives

• The number of XTRAC systems placed in dermatologists' offices in the U.S. decreased from 923 at the end of 2023 to 882 as of June 30, 2024.
• The company's revenue for the first half of 2024 decreased compared to the same period in 2023.
• The company experienced a decrease in gross profit for the first half of 2024 compared to the same period in 2023.
• The company's dermatology recurring procedures revenue decreased in both Q2 and the first half of 2024 compared to the same periods in 2023.

Risks

• The company is subject to ongoing risks related to the COVID-19 pandemic, the Russia-Ukraine war, and the Israel-Hamas conflict, which could impact supply chains and customer behavior.
• The company faces potential sales tax liabilities in New York and California, with ongoing appeals and administrative processes.
• The company's ability to access financing could be affected by market conditions and rising interest rates.
• The company's success depends on building market acceptance for its products, particularly XTRAC and TheraClear, and achieving reimbursement from insurers.
• The company's reliance on a few key customers for a significant portion of its revenue poses a concentration risk.

Future Outlook

Management believes that the company's cash and cash equivalents, anticipated revenues, and operating expense management, along with the proceeds from the July 2024 equity raise, will be sufficient to satisfy the company's working capital needs for at least the next 12 months. However, market conditions could interfere with the company's ability to access financing on favorable terms.

Management Comments

• Management believes that several factors have an impact on the prescribed use of XTRAC treatments for psoriasis and vitiligo patients.
• The company reduced its direct-to-patient advertising over the course of 2023, which they believe contributed to a reduction in the number of XTRAC treatments compared to prior periods that continued into 2024.
• The company's strategy going forward is to increase its direct-to-patient program for XTRAC advertising in the United States.

Industry Context

The medical technology industry, particularly in dermatology, is experiencing ongoing challenges due to the COVID-19 pandemic, supply chain disruptions, and geopolitical conflicts. Strata Skin Sciences is navigating these challenges while also focusing on expanding its market reach and product offerings. The company's focus on recurring revenue models and direct distribution aligns with industry trends, but it faces competition and the need to demonstrate clinical and economic value to healthcare providers and patients.

Comparison to Industry Standards

• Strata's gross profit margin of 58.5% in Q2 2024 is within the range of other medical device companies, but it is important to note that the company's margin is influenced by its recurring revenue model and the sale of refurbished units.
• The company's net loss of $99,000 in Q2 2024 is an improvement compared to the same period last year, but it is still not profitable. Many medical device companies, especially those in the growth phase, may experience losses as they invest in research, development, and market expansion.
• The decrease in XTRAC system placements is a concern, as it indicates a potential slowdown in the company's core business. This contrasts with some competitors who are experiencing growth in their installed base.
• Strata's reliance on a few key customers for a significant portion of its revenue is a risk that is not uncommon in the medical device industry, but it is important to diversify the customer base to mitigate this risk.
• Compared to companies like InMode and Cutera, which also operate in the aesthetic and dermatology space, Strata's revenue is lower, and its profitability is more volatile. However, Strata's focus on excimer laser technology and its recurring revenue model differentiate it from these competitors.

Management Changes

Legal Proceedings

• The company is involved in ongoing legal proceedings related to sales tax assessments in New York and California.
• A proposed representative class action under California's Private Attorneys General Act (PAGA) was settled, with the company paying $106,000.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by ongoing cost-cutting measures and changes in the sales force.
• Customers may benefit from the company's focus on improving its products and services.
• Suppliers may be affected by supply chain disruptions and changes in the company's purchasing patterns.
• Creditors may be affected by the company's financial performance and its ability to meet its debt obligations.

Next Steps

• The company plans to increase its direct-to-patient advertising program for XTRAC in the United States.
• The company will continue to manage operating expenses and monitor the impact of external factors such as the COVID-19 pandemic and geopolitical conflicts.
• The company will continue to pursue appeals related to sales tax assessments in New York and California.
• The company will continue to evaluate its financing options and may seek additional capital if needed.

Key Dates

Keywords

XTRAC, TheraClear, dermatology, laser, psoriasis, vitiligo, acne, medical technology, recurring revenue, skin treatment